Feline Leukemia and Feline AIDS (FeLV-FIV) Treatment Aid Is Now Available in New 3-Pack

Lymphocyte T-Cell Immunomodulator (LTCI) from IMULAN BioTherapeutics, the first and only approved treatment aid in the United States for Feline Leukemia Virus (FeLV) and Feline Immunodeficiency Virus (FIV or Feline AIDS) infections, is now available in an affordable three-dose pack designed for new patients.

Scottsdale, Arizona (PRWEB) March 28, 2008 -- IMULAN BioTherapeutics (http://www.imulan.com) (IMULAN) announced the release of a three-dose pack of Lymphocyte T-Cell Immunomodulator (LTCI), the first and only approved treatment aid in the United States for Feline Leukemia Virus (http://www.imulan.com/felv-fiv-treatment.html) (FeLV) and Feline Immunodeficiency Virus (http://www.imulan.com/felv-fiv-treatment.html) (FIV or Feline AIDS) infections. Until now, LTCI was only available in ten-dose packs.

Dr. Craig Woods, CEO of IMULAN, stated, "IMULAN is pleased to offer a new affordable three-dose pack of LTCI, which has been designed as a starter pack for cats recently diagnosed with Feline Leukemia or FIV. We will still be offering the ten-dose pack as well for long term maintenance of feline patients."

Lymphocyte T-Cell Immunomodulator is a naturally occurring substance produced by the body. In previous studies, Lymphocyte T-Cell Immunomodulator has demonstrated improvement in the clinical symptoms and lymphocyte counts in cats infected with FeLV and FIV.

LTCI is only available through licensed veterinarians in the United States. Pet owners are encouraged to contact their veterinarian for additional information about LTCI.

For additional information on LTCI or IMULAN, please call 877-892-9595 or visit www.IMULAN.com.

About Lymphocyte T-Cell Immunomodulator: LTCI is a conditionally approved treatment aid for cats infected with Feline Leukemia Virus (FeLV) and/or Feline Immunodeficiency Virus (FIV). Conditional licenses are granted by the United States Department of Agriculture Center for Veterinary Biologics to products that have met reasonable expectation of efficacy, have demonstrated purity, and passed safety testing. LTCI is manufactured by T-Cyte Therapeutics, Inc. and is exclusively distributed by IMULAN BioTherapeutics, LLC.

About IMULAN BioTherapeutics: IMULAN is a privately held bioscience company focused on providing innovative solutions for complex animal diseases. IMULAN's policy is to provide veterinarians access to conditionally approved products for diseases where no current approved therapy is available. IMULAN's products give animal owners better solutions for their pet's diseases.

Contact:

Dr. Craig Woods, CEO

IMULAN BioTherapeutics

877.892.9595

cwoods(at)imulan.com

###